Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The p53 tumor suppressor is a potent transcription factor that plays a key role in the regulation of cellular responses to stress. It is controlled by its negative regulator MDM2, which binds directly to p53 and inhibits its transcriptional activity. MDM2 also targets p53 for degradation by the proteasome. Many tumors produce high levels of MDM2, thereby impairing p53 function. Restoration of p53 activity by inhibiting the p53-MDM2 interaction may represent a novel approach to cancer treatment. RG7112 (2g) is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket of MDM2. In cancer cells expressing wild-type p53, RG7112 stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“By binding to MDM2, RG-7112 inhibits the interaction between p53 and MDM2, preventing the degradation of the p53 proteasome, which leads to stabilization and increased levels of the tumor suppressor protein p53 in the cell.369”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [369]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“MDM4 amplification was even shown to reduce sensitivity of cells to Nutlin-3 [29–31].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“WB138 increases the levels of both p53 and MDM2, which is consistent with the activity of previous reports on MDM2 inhibitors[28,32–36].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [35]
In the citing paper
“RG7112 was modified by Roche based on the structure of Nutlins and was the first to be introduced into clinical trials (Fig. 4) [19].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [19]
In the citing paper
“The crystal structure showed that the 4-chlorophenyl ring occupied the Trp23 and Leu26 pockets, while the ethoxy group was prominently located in the Phe19 pocket341 (Fig. 8d).”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [341]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Self-citationRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Self-citation
Research works printed but not linked: 2
- Iwakuma T., 2003, Mol. Cancer Res., 1, 993
- Vu B. T., 2011, Curr. Top. Microbiol. Immunol., 348, 151
Cited by
Items 301–400 of 453
Protein–Protein Interaction Inhibitors
Hardcastle, I. R. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_27 · Cited by 4
In Silico Tools in PROTACs designPreprint
Wei, M. (2023) · arXiv (Cornell University) · doi:10.48550/arxiv.2307.01320 · Cited by 4
Kaushik, A. C., Talware, S. K., & Siddiqi, M. I. (2025) · Briefings in Functional Genomics · doi:10.1093/bfgp/elaf006 · Cited by 3
Chemical adaptation: bridging synthetic chemistry with drug development
Ding, K., Li, Y., Zhou, Y., & Huang, W. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3223-4 · Cited by 3
BRD4: From molecular understanding to therapeutics development
Wu, S.-Y., & Chiang, C. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.07.004 · Cited by 3
Bajelan, B., Zaki‐Dizaji, M., Darabi, S., & Rajaei, F. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27798 · Cited by 3
Suppression of MRPL23 induces cellular senescence in hepatocellular carcinoma by targeting HMGB1
Huang, Y.-B., Xu, S.-M., Li, M., Chen, J., Lu, C., & Liu, Q. (2025) · Discover Oncology · doi:10.1007/s12672-025-02885-6 · Cited by 3
Antiangiogenic and antitumoral activity of LQFM126 prototype against B16F10 melanoma cells
da Silva, A. C. G., Rodrigues, B. D. S., Andrade, W. M., dos Santos, T. R. M., de Carvalho, F. S., Lobón, G. S., Vaz, B. G., Lião, L. M., Menegatti, R., & Valadares, M. C. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109127 · Cited by 3
Han, X., Du, J., Shi, D., Li, L., Li, D., Zhang, K., Lin, S.-W., Zhu, J., Huang, Z., Zhou, Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213867 · Cited by 3
Sustainable Drug Substance Processes Enabled by Catalysis
Püntener, K., Hildbrand, S., Stahr, H., Schuster, A., Iding, H., & Bachmann, S. (2024) · Wiley eBooks · doi:10.1002/9781119870647.ch28 · Cited by 3
The synthesis and characterization of tetramic acid derivatives as Mdm2-p53 inhibitors
Muszak, D., Łabuzek, B., Brela, M. Z., Twarda‐Clapa, A., Czub, M., Musielak, B., Surmiak, E., & Holak, T. A. (2019) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2019.03.089 · Cited by 3
Sim, R. R. Y., Yang, C. H., & Yang, Y. Y. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.3c01101 · Cited by 3
Bazanov, D. R., & Lozinskaya, N. A. (2024) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202400305 · Cited by 3
Fishlock, D., Diodone, R., Hildbrand, S., Kuhn, B., Moessner, C., Peters, C., Rege, P. D., Rimmler, G., & Schantz, M. (2018) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2018.492 · Cited by 3
Verma, S., & Pandey, A. K. (2021) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-021-00286-7 · Cited by 3
Computational prediction and validation of specific EmbR binding site on PknH
Na, I., Dai, H., Li, H., Gupta, A., Kreda, D., Zhang, P., Chen, X., Zhang, L., & Alterovitz, G. (2021) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2021.11.006 · Cited by 3
Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé
Szakács, Z., & Alizadeh, H. (2022) · Hematológia–Transzfuziológia · doi:10.1556/2068.2022.00151 · Cited by 3
Targeting breast cancer senescence in 3D models of bone metastasis
Hamburger, E. C. B., Garakani, M. M., Ghazizadeh, S., Alfaisali, S., Ouellet, J. A., Weber, M. H., Garzia, L., Haglund, L., & Rosenzweig, D. H. (2026) · Breast Cancer · doi:10.1007/s12282-026-01857-0 · Cited by 2
Qie, B., Li, J., Wan, M., & Zhu, Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126298 · Cited by 2
Deng, X., Ablise, M., Xiamuxi, H., Yan, T., Imam, M., Wang, Y., Zu, M., & Wumaier, W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1715712 · Cited by 2
The Bat Blueprint: Translating Mitochondrial Adaptations into Next-generation Therapeutics
An, K., Hwang, D., Park, S., Jung, D., Jeong, S.-H., Hyun-Seok, J. I. N., Kim, C., Ahn, K., Ahn, Y., & Hwang, Y.-K. (2026) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2026.32.1.1 · Cited by 2
Discovery of 1,2‐Naphthoquinone Derivatives as Potent p53‐MDM2 Interaction Inhibitors
Jung, M. E., Go, A., Yoo, D., Chae, J., Jeon, M., Lim, B., & Choi, G. (2019) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.11897 · Cited by 2
Research Progress on Small Molecule Inhibitors of MDM2-p53 Protein-protein Interaction
Hu, M. Y., Xu, C., Xu, M., He, S., & Liu, D. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206358340250121060830 · Cited by 2
Shemorry, A., den Besten, W., Mulvihill, M. M., Essenburg, C. J., Blaquière, N., Kleinheinz, T., Villemure, E., Peale, F., Deshmukh, G. S., Maddalo, D., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.008 · Cited by 2
A Medicinal Chemistry Perspective on the Hit‐to‐Lead Phase in the Current Era of Drug Discovery
Brown, D. G. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677047.ch12 · Cited by 2
Alzheimer's Disease and Cancer: Common Targets
Yang, X., Dai, J., Wu, C., & Liu, Z. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575263108231031132404 · Cited by 2
Ntwasa, M. M. (2024) · Cells · doi:10.3390/cells13131124 · Cited by 2
Teh, T. R. D., Fernandez, K. C. J., Cruz, M. K. D. M., Moreno, P. G. G., Nacario, R. C., Completo, G. C. J., & Heralde, F. M. (2024) · Acta Medica Philippina · doi:10.47895/amp.vi0.10777 · Cited by 2
Klebe, G. (2024) · Springer eBooks · doi:10.1007/978-3-662-68998-1_10 · Cited by 2
Zhuang, C., & Sheng, C. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_2 · Cited by 2
An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors
Xue, X., Bao, G., Zhang, H.-Q., Zhao, N.-Y., Sun, Y., Zhang, Y., & Wang, X. (2018) · Molecules · doi:10.3390/molecules23123174 · Cited by 2
E3 ubiquitin ligase components in GtoPdb v.2022.1
Faccenda, E., & Layfield, R. (2022) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f1023/2022.1 · Cited by 1
E3 ubiquitin ligase components in GtoPdb v.2022.3
Faccenda, E., & Layfield, R. (2022) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f1023/2022.3 · Cited by 1
E3 ubiquitin ligase components in GtoPdb v.2023.2
Faccenda, E., & Layfield, R. (2023) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f1023/2023.2 · Cited by 1
Xu, N., Tong, Y., Ma, K., Jiang, L., & Zheng, W. (2025) · Medical Oncology · doi:10.1007/s12032-025-02912-0 · Cited by 1
Overview of Drug Discovery Targeting PPI Systems
Ma, H., & Zhang, J. (2025) · Wiley eBooks · doi:10.1002/9783527845828.ch2 · Cited by 1
Zhang, A., Tang, B., Zhou, S., Sui, C., He, S., Liu, Y., Li, M., & Qian, Y. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118410 · Cited by 1
Illuminati, D., Foschi, R., Marchetti, P., Zanirato, V., Fantinati, A., Trapella, C., Voltan, R., & Cristofori, V. (2025) · Molecules · doi:10.3390/molecules30193908 · Cited by 1
El-Zoheiry, H. H., Ahmed, R. F., Elkotamy, M. S., Abdel‐Aziz, H. A., & Elmasry, G. F. (2026) · Drug Development Research · doi:10.1002/ddr.70277 · Cited by 1
ElSawy, K. M. (2026) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2026.129591 · Cited by 1
Senolytic Therapy as a Preventive Strategy for Spine Degeneration and Pain
Darband, S. G., Cherif, H., Mannarino, M., Sagir, J., Millecamps, M., Ouellet, J. A., Stone, L. S., & Haglund, L. (2026) · Advanced Science · doi:10.1002/advs.202522770 · Cited by 1
Wei, Y., Yu, J., Wang, C., & Xu, J. (2026) · Organic Chemistry Frontiers · doi:10.1039/d6qo00750c · Cited by 1
Resistance of human primary mesenchymal stem cells to cytotoxic effects of nutlin‐3 in vitro
Bajelan, B., Zaki‐Dizaji, M., Rahmani, B., Darzi, S., Darabi, S., & Rajaei, F. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29324 · Cited by 1
Overview of Protein-Protein Interactions and Small-Molecule Inhibitors Under Clinical Development
Dong, G., & Sheng, C. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_1 · Cited by 1
Yang, Y., Dong, Z., Hu, H., Peng, J., Sheng, Y., Yang, T., Yuan, S., Li, Z., Yang, J., Wells, T., et al. (2019) · The Analyst · doi:10.1039/c9an00350a · Cited by 1
Tian, Y., Lahue, B. R., Ma, Y., Nair, L. G., Pan, W., Doll, R. J., Guzi, T. J., Ma, Y., Wang, Y., & Bogen, S. L. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128625 · Cited by 1
Zhou, M., Lin, Y., Chen, X., Xu, G., Chung, L. W., & Tang, W. (2023) · Angewandte Chemie · doi:10.1002/ange.202300334 · Cited by 1
Pharmacophore Modeling Guided by Conformational Dynamics Reveals Potent Anticancer Agents
Kantarci-Carsibasi, N. (2023) · Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi · doi:10.19113/sdufenbed.1121167 · Cited by 1
Small-Molecule Inhibitors of Protein–Protein Interactions as Therapeutics
Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_7 · Cited by 1
New N-substituted 2,4,5-triarylimidazolines: synthesis and antitumor activity
Султанова, Р. М., Bazanov, D. R., Kuleshina, G. Z., Lozinskaya, N. A., Svirshchevskaya, E. V., & ZLOTSKII, S. S. (2024) · Russian Chemical Bulletin · doi:10.1007/s11172-024-4483-4 · Cited by 1
Pant, P., Sehgal, A., Gupta, T., & Sharma, P. (2025) · Journal of Peptide Science · doi:10.1002/psc.70033 · Cited by 1
New Approaches to Managing Liposarcoma: Will Cold Steel Remain the Only Way to Heal?
Ami, E. A. B., & George, S. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.010280 · Cited by 1
Rosso, M. (2015) · CUNY Academic Works (City University of New York) · Cited by 1
NMR studies of folded and disordered proteins and bicelle systems
Dudás, E. F. (2020) · Eötvös Loránd Tudományegyetem · doi:10.15476/elte.2019.091 · Cited by 1
Chmara, J. (2016) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2016-11527 · Cited by 1
Inhibition of the MDM2/p53 Interaction Design, Synthesis and Evaluation of MDM2 Inhibitors
Pettersson, M. (2015) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Small molecules that affect the p53 pathway and their potential use in the treatment of cancer
Sachweh, M. C. C. (2014) · Figshare
Pasello, G. (2015) · Padua@research (University of Padova)
Synthese und Evaluierung stabilisierter Bindungsepitope zur Adressierung kleiner GTPasen
Spiegel, J. (2016) · Technische Universität Dortmund Eldorado (Technische Universität Dortmund) · doi:10.17877/de290r-16904
Draganov, A. B. (2016) · Digital Archive @ GSU · doi:10.57709/8476886
Improving the process synthesis, potency, and pharmacokinetics of the anticancer compound PAC-1
Roth, H. S. (2015) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Leão, M. V. C. F. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/s5d0-7g43
Ickes, A. R. (2016) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Multifunctional Scaffolds for Selective Protein-Protein Inhibition
Rodriguez‐Marin, S. (2016) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Molecular Designing of Small-Molecule Inhibitors for Apoptosis Regulation
Yoshimori, A., & Tanuma, S. (2017) · Current human cell research and applications · doi:10.1007/978-981-10-7296-3_10
Li, Y. (2018) · Deep Blue (University of Michigan)
Increasing Chemosensitivity in Colorectal Cancer
Agro, L. A. (2019) · TSpace (University of Toronto)
Macrocyclic peptides as inhibitors of protein-protein interactions
Smith, F. R. (2020) · Nottingham ePrints (University of Nottingham)
Seeking for new p53-activating agents: effective therapies for colorectal cancer
Rocha, H. I. N. R. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/f7r1-4t55
Rew, Y., & Eksterowicz, J. E. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016544-00280
Expanding the Spiroligomers Toolbox as Protein-Protein Interaction Inhibitors
Akula, K. (2017) · TUScholarShare (Temple University)
Characterization and modulation of 14-3-3σ protein-protein interactions
Kuusk, A. (2020) · TU/e Research Portal
Investigation of Resistant Mechanisms of Apoptosis-inducing Anticancer Agents.
Hoffman-Luca, C. G. (2015) · Deep Blue (University of Michigan)
Cancer Targets Involving the Ubiquitin Proteasome System
Araujo, E. M. V. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc282
MDM2 inhibitors: Targeting p53-MDM2 interaction to anti-cancer
Zhang, X. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202130802015
E3 ubiquitin ligase components in GtoPdb v.2021.3
Faccenda, E., & Layfield, R. (2021) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f1023/2021.3
Cao, F., Chen, L., Xiong, F., Liu, X., & Zhang, L. (2021) · Research Square · doi:10.21203/rs.3.rs-905935/v1
A Novel Intramolecular Interaction in P53
He, F. (2020) · Digital Commons - University of South Florida (University of South Florida)
Der Tumorsuppressor p53 reguliert HSF1 im Modell des kolorektalen Karzinoms
Stender, A. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8711
Cao, F., Liang, C., Xiong, F., Li, H., Liu, X., & Zhang, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1410429/v1
Ohsawa, K. (2015) · Springer theses · doi:10.1007/978-4-431-55447-9_1
Faculty Opinions recommendation of Emerging new concepts of degrader technologies.
Bernstein, P. R. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737971820.793576450
Hoppe, T. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.731966527.793570381
Reativação da p53 Usando Pequenas Moléculas para Terapia Anticancerígena
Santos, M. M. M., Ferreira, R., & Pacheco, P. A. F. (2023) · Boletim da Sociedade Portuguesa de Química · doi:10.52590/m3.p705.a30002636
Research progress in small-molecule modulators of protein-protein interactions
Yang, B., & Qi, X. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0034
E3 ubiquitin ligase components in GtoPdb v.2023.1
Faccenda, E., & Layfield, R. (2023) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f1023/2023.1
Impact of p53-dependent Networks on Prognosis of chronic lymphocytic leukemia
Atia, E. A. M. M., mohammed, M., Ahmed, E., & El-Khazragy, N. N. (2023) · Egyptian Journal of Pure and Applied Science · doi:10.21608/ejaps.2023.223757.1067
Klebe, G. (2023) · Springer eBooks · doi:10.1007/978-3-662-67209-9_10
E3 ubiquitin ligase components in GtoPdb v.2023.3
Faccenda, E., & Layfield, R. (2023) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f1023/2023.3
Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
Wang, F., Chen, L., Zhang, L., Du, S., & Feng, Y. (2024) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-024-00616-0
Kurt, B., Kayhan, H., Özgür, E., Kartal, Y. K., & Kısmalı, G. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5055115
Targeting the Ubiquitin-Proteasome System in cancer
Spallek, R., McLaughlin, C., & Sapkota, G. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00078-9
Kunig, V. B. K. (2021) · Technische Universität Dortmund Eldorado (Technische Universität Dortmund) · doi:10.17877/de290r-22400
Pairawan, S., Zhao, M., Yuca, E., Annis, A., Evans, K., Sutton, D., Carvajal, L., Ren, J.-G., Santiago, S., Guerlavais, V., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14167900
Moody, J. (2014) · ResearchWorks at the University of Washington (University of Washington)
Evaluation of Senolytic Drugs o-Vanillin and RG-7112 in Painful Intervertebral Disc Degeneration
Mannarino, M. (2023) · eScholarship@McGill (McGill) · doi:10.82308/52304
Metadata
- Authors
- Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., Tovar, C., Packman, K., Vassilev, L., & Graves, B.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Discovery Chemistry, ‡Discovery Oncology, §Discovery Technologies, ∥Non-Clinical Development, Roche Research Center, Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
- Corresponding author
- Vu, Binh
- ORCID
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-04-04
- Volume
- 4
- Issue
- 5
- Pages
- 466-469
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC4027145
- OpenAlex
- W1985567682
- Cited by
- 395
- References
- 24
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 28 · 2023: 39 · 2022: 39 · 2021: 36 · 2020: 39 · 2019: 39 · 2018: 19 · 2017: 19 · 2016: 16 · 2015: 28 · 2014: 20 · 2013: 8
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- RG7112, MDM2 inhibitors, p53, p53-MDM2 interaction, small molecule drug discovery, p53 stabilization, cancer therapy, cell cycle arrest, apoptosis, tumor xenografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.